Long-acting inhaled bronchodilators for COPD - Lack of logic continues

New Zealand Medical Journal

Volumn 118, Issue 1222, 2005, Pages

  Jones, David ^a,b  

^a CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^b WELLINGTON HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FORMOTEROL; FORMOTEROL FUMARATE; SALMETEROL; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; SALBUTAMOL; SCOPOLAMINE DERIVATIVE; TIOTROPIUM;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG INDICATION; DRY POWDER; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; POWDER INHALER; QUALITY OF LIFE; SYMPTOMATOLOGY; DRUG APPROVAL; INHALATIONAL DRUG ADMINISTRATION; NEW ZEALAND; PUBLIC HEALTH; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; DRUG APPROVAL; ETHANOLAMINES; HUMANS; NATIONAL HEALTH PROGRAMS; NEW ZEALAND; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 27244461223     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Joint Health Surveys Unit, SPCR. Health Survey for England 1995. London: TSO; 1997.
2. Royal College of General Practitioners, Office of Populations Censuses and Surveys, Dept of Health, Morbidity statistics from general practice. Third National Study, 1981-82. London: HMSO; 1986.
3. Goldcare MJ, Ferguson JA. Inpatient workload in medical specialties I: demographic profiles and time trends from linked statistics. Q J Med. 1995;88:649-60.
4. Gross PC, Anderson GF, Powe NR. The relation between funding by the national institutes of health and the burden of disease. N Engl J Med. 1999;340:1881-7.
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Executive Summary updated 2004 (based on April 1998 National Heart Lung & Blood Institute and World Health Organisation workshop). Available online. URL: http://www.goldcopd.com/ Accessed September 2005.
6. Calverley P. Breathlessness during exercise in COPD: how do the drugs work? Thorax. 2004;59:455-7.
7. O'Donnell D, SM Ravel, KA Webb. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:770-7.
8. ibid page 12. Table 8 - Therapy at each stage of COPD.
9. Boyd G, Morice H, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease. Eur Respir J. 1997;10:815-21.
10. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778-84.
11. Van Noord JA, Aumann J-L, Janssen E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214-22.
12. Chapman K, Kuipers AT, Goldstein R, et al. Addition of salmeterol 50 mcg bd to anticholinergic treatment in COPD. Am J Respir Crit Care Med. 1999;159:A523.
13. Dauletbaev N, Viel K, Bargon J. Salmeterol or ipratropium bromide/fenoterol in stable mild to moderate COPD. Eur Resp J. 2001;18(Suppl 33):426S.
14. Casaburi R, Mahler DA, Jones PW. A long term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-24.
15. Casaburi R, Kukafka D, Cooper C, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127:809-17.
16. Man W, Mustfa N, Nikoletau D, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004;59:471-6.
17. Niewoehner D, Rice K, Cote C, et al. Reduced COPD exacerbations and associated healthcare utilisation with once daily tiotropium (TIO) in the VA medical system. Am J Respir Crit Care Med. 2004;169:A207.
18. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during one year's treatment with tiotropium. The Dutch/Belgian Tiotropium study group. Eur Respir J. 2002;19:209-16.
19. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404.
20. Oosterbrink JB, Rutten-van Molken MP, Monzu BU, FitzGerald JM. Probabilistic Markov model to assess the cost-efectiveness of bronchodilator therapy in COPD patients in different countries. Value in Health. 2005;8:32-46.
21. Oostenbrink JB, Rutten-van Molken MP, Al MJ, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J. 2004;23:241-9.
22. Friedman M, Menjoge SS, Anton SF, Keston S. Healthcare costs with tiotropium plus usual care v usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics. 2004;22:741-9.